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Effect of Different Drugs Influencing Monoamine
Neurotransmission on Haloperidol-Induced
Catalepsy in Mice
Aim: Catalepsy occurs following high dopamine D2 receptor blockade by the typical antipsychotic drug
haloperidol. The present study investigated the effect of different drugs affecting monoamine
neurotransmission in this animal model of Parkinson's disease in mice.
Materials and Methods: Drugs were intraperitoneally administered with haloperidol 30 min prior to testing.
Catalepsy was measured using the bar test.
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Results: Catalepsy duration was reduced by the non-selective noradrenaline and serotonin reuptake
inhibitors imipramine and amitriptyline (21.1% and 22.3% reduction by 20 mg/kg imipramine and
amitriptyline, respectively). Catalepsy duration was increased by the selective serotonin reuptake inhibitors
(SSRIs) fluoxetine, fluvoxamine, and citalopram and by the serotonin receptor antagonist and reuptake
inhibitor nefazodone (maximal increases of 112.4%, 38.5%, 30.8% and 112.4%, respectively). In
contrast, the duration of catalepsy was decreased by the serotonin and dopamine reuptake inhibitor
sertraline (56.8%, 52.6%, 35.7%); by sibutramine, a serotonin, dopamine and noradrenaline reuptake
inhibitor (56.8%, 52.6%, 35.7%); and by Hypericum perforatum (31.9%, 33.2%, 39.6%) at 5, 10, 20
mg/kg, respectively.
Conclusions: Taken together, data in the present study suggest that drugs which have been reported to
increase brain extracellular dopamine levels are likely to benefit motor symptoms in patients with Parkinson's
disease.
Key Words: Catalepsy, haloperidol, antidepressants, mice

Monoamin ‹letimini Etkileyen Farkl› ‹laçlar›n Ratlarda Haloperidol ile Uyar›lm›ﬂ
Katalepsi Üzerine Etkisi
Amaç: Tipik bir antipsikotik olan haloperidol dopamine D2 reseptörlerini bloke ederek katelepsi oluﬂturur.
Farelerde Parkinson hastal›¤› oluﬂturulan bu modelde farkl› ilaçlar›n monoaminin sinir iletimi üzerine olan etkisi
araﬂt›r›ld›.
Yöntem ve Gereç: Haloperidolle birlikte ilçalar testten 30 dk once intraperitoneal olarak verildi. Katalepsi bar
testi kullan›larak ölçüldü.
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Bulgular: Katalepsi süresi selektif olmayan noradrenalin ve serotonin reuptake inhibitörleri imipramin ve
amitriptilin verilmesi ile azalt›ld›. (20mg/kg imipramin ve amitriptilin verilmesi ile s›ras›yla %21.1 ve %22.3).
Seçici olarak serotonin reuptake inhibisyonu yapan fluoksetine, fluvoksamine, citalopram ve serotonin reseptör
antagonisti ve reuptake inhibitörü olan nefazodone ise katalepsi süresini uzatt›. (maksimum art›ﬂlar %112.4,
%38.5, %30.8 ve %112.4). Karﬂ›t olarak katalepsi süresi dopamine ve serotonin reuptake inhibitörü setraline
taraf›ndan azalt›ld› (%56.8, %52.6, %35.7). Benzer eﬂekilde serotonin, dopamine ve noradrenalin reuptake
inhibitörü olan sibutramin (%76.8, %82.2 and %89.1) ve Hypericum perforatum da katalepsi süresini azaltt›
(%31.9, %33.2, %39.6).
Sonuç: Bütün veriler göz önüne al›nd›¤›nda beyinde ekstrasellüler dopamin düzeylerini art›ran ilaçlar›n
Parkinson hastal›¤›nda motor semptomlar›n düzeltilmesinde yararl› olaca¤› kanaatine var›ld›.
Anahtar Sözcükler: Katalepsi, haloperidol, antidepresanlar, fare
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Introduction
Parkinson’s disease is a progressive neurodegenerative
disorder, the principal pathological characteristic of which
is the loss of dopaminergic neurons of the substantia nigra
pars compacta. Patients with Parkinson’ disease suffer
from motor behavioral impairment in the form of
muscular rigidity and bradykinesia in addition to a resting
tremor (1). Studies have indicated that depression is a
common and potentially debilitating aspect of Parkinson's
disease, affecting 40-50% of patients (2,3). Depression in
Parkinson's disease might be associated with a specific loss
of dopamine and noradrenaline innervation in the limbic
system (4). Depression associated with Parkinson's disease
is likely to contribute to the development of cognitive
disorders and is associated with a significantly increased
risk of developing dementia (5,6). Thus, antidepressant
drugs are likely to be included in the list of drugs
prescribed for patients with Parkinson's disease. For many
years, the tricyclic antidepressants (TCAs) and the
monoamine oxidase inhibitors (MAOIs) have dominated the
pharmacological treatment of depressive disorders.
Selective serotonin reuptake inhibitors (SSRIs) have
comparable efficacy to the TCAs and a better tolerability
profile in patients with depression; they are rapidly being
considered as first-line therapy for patients with
depressive disorders including that occurring in
Parkinson’s disease patients (7,8).
Questions, however, have arisen considering the safety
of SSRIs in Parkinson's disease. In reports of adverse
reactions in patients given fluoxetine, there were
notifications of extrapyramidal events that may be caused
by the drug (9), and among patients with Parkinson's
disease treated with SSRIs, there were cases of worsening
parkinsonism (10). The addition of sertraline (11,12) or
citalopram (13) to the antiparkinsonian drug regimen has
also been associated with treatment-emergent
extrapyramidal syndrome side effects. The risk estimate of
SSRIs causing extrapyramidal symptoms appeared to be
higher in patients concurrently using antipsychotic
medication (14). In addition, the start of SSRI therapy in
levodopa users was followed by a faster increase in
antiparkinsonian drug treatment (15). Alterations in
serotonergic neurotransmission have been suggested to be
involved in the modulation of the basal ganglia and in the
pathophysiology of human involuntary movement disorders.
There is also an evidence to suggest abnormalities of 5hydroxytryptamine (HT)2C transmission in the basal ganglia
of patients with Parkinson's disease (16).
334
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The aim of this study was to examine drugs
influencing monoamine mechanisms, especially those used
in the treatment of depressive disorders, in an animal
model of Parkinson’s disease caused by injection of
haloperidol in mice. Compounds studied included the
conventional TCAs, imipramine and amitriptyline; the
SSRIs fluoxetine, fluvoxamine and sertraline; the
serotonin receptor antagonist and reuptake inhibitor
nefazodone; and Hypericum perforatum (St. John's wort)
extract, which acts to inhibit the re-uptake of several
neurotransmitters, including serotonin, norepinephrine,
dopamine, gamma-aminobutyric acid and L-glutamate
(17-19). In addition, the effect of sibutramine, a drug
used in obesity that weakly inhibits norepinephrine and 5HT reuptake (20), was examined.
Catalepsy, a behavioral immobility associated with
varying degrees of enhanced muscular rigidity, serves as
an experimental animal model of parkinsonism (21).
Typical antipsychotics, such as haloperidol, produce
extrapyramidal side effects, including a parkinsonian-like
syndrome which is attributed to blockade of D2 in the
striatum (22). Catalepsy induced by haloperidol
represents a useful model of Parkinson’s disease and has
been used for detecting antipsychotic drugs with
extrapyramidal side effect liability (23,24) and for
evaluating the utility of antidepressant drugs for the
treatment of depression associated with Parkinson’s
disease (25,26).

Materials and Methods
Male Swiss albino mice (22-25 g) were used. Mice
were housed under standardized conditions with free
access to food and water. Catalepsy, defined as a reduced
ability to initiate movement and a failure to correct
posture, was measured by means of the bar test. To test
for catalepsy, mice were positioned so that their
hindquarters were on the bench and their forelimbs
rested on a 1 cm diameter horizontal bar, 4 cm above the
bench. The length of time the mice maintained this
position was recorded by stopwatch to a maximum of
180 s. This procedure was conducted 30 min after drug
administration. Haloperidol was administered via
intraperitoneal (i.p.) route at the dose of 2 mg/kg. The
tested drug was administered intraperitoneally together
with haloperidol. Mice were judged to be cataleptic if they
maintained this position for 30 s or more.
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Drugs
Haloperidol (Kahira Pharm and Chem. IND, Cairo,
ARE), fluoxetine hydrochloride (Amoun Pharmaceuticals,
Cairo, ARE), imipramine hydrochloride, (Novartis
Pharmam Cairo, ARE), amitriptyline hydrochloride
(Kahira Pharm and Chem. IND, Cairo, ARE), nefazodone
hydrochloride (Bristol Myers Squibb, Cairo, ARE),
sertraline hydrochloride (Pfizer, Cairo, ARE), citalopram
hydrobromide (Lundbeck, Denmark), fluvoxamine
maleate (Solvay Pharmaceuticals, Holland), sibutramine
hydrochloride (EVA Pharma, Cairo, ARE), and St. John's
wort (Hypericum perforatum) extract (Safamood, ATOS
Pharma, Cairo, ARE) were used. The doses of drugs
employed in the study were based upon the human dose
after conversion to that of rat (27).
Statistics
All results are expressed as mean ± SE. Multiple group
comparisons were performed by one-way analysis of
variance followed by Duncan multiple range test. P <
0.05 was considered statistically significant.

Results
Results are presented in Table 1. Haloperidol
administered i.p. at the dose of 2 mg/kg produced a
significant cataleptic response. The duration of
haloperidol-induced catalepsy was significantly reduced,
by 13.4% and 21.1%, by 10 and 20 mg/kg imipramine,
respectively. Amitriptyline at 20 mg/kg significantly
reduced catalepsy, by 22.3%. Sertraline (5, 10, 20
mg/kg) markedly decreased catalepsy by 56.8%, 52.6%
and 35.7%, respectively. The effect of haloperidol was
significantly and potently inhibited by sibutramine
(76.8%, 82.2% and 89.1%, at 5, 10, 20 mg/kg,
respectively). The duration of catalepsy was also
decreased dose-dependently by Hypericum perforatum
(31.9%, 33.2% and 39.6%, at 5, 10 and 20 mg/kg,
respectively). In contrast, the SSRIs fluoxetine,
fluvoxamine and citalopram increased haloperidol-induced
catalepsy. The effect of haloperidol was significantly
increased by 18% and 112.4% after fluoxetine 10 and
20 mg/kg, by 22% and 38.5% after fluvoxamine 10 and
20 mg/kg, and by 21% and 30.8% after citalopram 10
and 20 mg/kg, respectively. Catalepsy was also
significantly increased by all doses of nefazodone
(61.6%, 84.1% and 112.4% increase by 5, 10 and 20
mg/kg, respectively).
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Table 1. Effect of different drugs acting on monoamine transmission
on the duration of haloperidol-induced catalepsy in mice.
Treatment

Duration of
catalepsy (sec)

Saline
Imipramine
5 mg/kg
10 mg/kg
20 mg/kg

63.6 ± 3.5
67.2 ± 2.6
55.1 ± 2.7
50.2 ± 3.6*

% inhibition
(vs control value)

-13.4%
-21.1%

Saline
Amitrpitiline
5 mg/kg
10 mg/kg
20 mg/kg

68.6 ± 3.5
59.1 ± 3.6
51.4 ± 4.3*

-10.2%
-22.3%

Saline Sertraline
5 mg/kg
10 mg/kg
20 mg/kg

79.8 ± 8.7
34.5 ± 5.7*
37.8 ± 5.4*
51.3 ± 5.1*

-56.8%
-52.6%
-35.7%

Saline 77.1 ± 6.7
Sibutramine
5 mg/kg
10 mg/kg
20 mg/kg

17.9 ± 1.6*
13.7 ± 1.2*
8.4 ± 0.7*

-76.8%
-82.2%
-89.1%

Saline
Hypericum
perforatum
5 mg/kg
10 mg/kg
20 mg/kg
Saline
Fluoxetine
5 mg/kg
10 mg/kg
20 mg/kg
Saline
Fluvoxamine
5 mg/kg
10 mg/kg
20 mg/kg
Saline
Citalopram
5 mg/kg
10 mg/kg
20 mg/kg
Saline
Nefazodone
5 mg/kg
10 mg/kg
20 mg/kg

65.8 ± 3.1

79.7 ± 5.6

54.3 ± 5.6*
53.2 ± 5.3*
48.1 ± 2.1*

-31.9%
-33.2%
-39.6%

53.2 ± 5.8
43.6 ± 5.4
62.8 ± 6.8
113.0 ± 10.8*

+18.0%
+112.4%

96.4 ± 6.1
78.6 ± 8.0
117.6 ± 6.2*
133.5 ± 7.8*

+22.0%
+38.5%

73.3 ± 6.2
83.6 ± 6.2
88.6 ± 5.6
95.9 ± 7.8*

+14.1%
+21.0%
+38.8%

73.3 ± 5.1
118.5 ± 12.5*
135.0 ± 11.4*
155.7 ± 9.9*

+61.6%
+84.1%
+112.4%

Catalepsy was induced by intraperitoneal administration of haloperidol
at the dose of 2 mg/kg. Tested drug was administered intraperitoneally
together with haloperidol. Catalepsy was measured by means of the bar
test 30-min after drug administration. P<0.05 compared to salinetreated control group (one-way ANOVA and Duncan multiple range
test).
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Discussion
The present study investigated the effect of a number
of drugs influencing monoamine neurotransmission on
catalepsy induced in mice by haloperidol. Findings in the
present study indicated that the duration of catalepsy was
decreased by the tertiary amine tricyclics, imipramine and
amitriptyline, which is in accordance with other earlier
studies (25,28). These agents, which served as the
cornerstone of antidepressant therapy for almost 30
years, are non-selective noradrenaline and to much less
extent serotonin reuptake inhibitors. In contrast to other
antidepressant drugs such as the SSRIs, the tertiary
amine tricyclics possess anticholinergic and antihistaminic
properties, which are likely to be of relevance to the
effects of these agents on catalepsy.
Fluoxetine, the prototype of SSRIs and one of the
most commonly used drugs as first-line therapy in
pharmacotherapy of depression (29), increased catalepsy
caused by haloperidol in the present study. Other
investigators have reported a decrease in haloperidol
catalepsy in mice by fluoxetine, the effect being more
evident with 5 mg/kg than with the higher dose of 25
mg/kg (26). In the present study, however, the
administration of 5 mg/kg fluoxetine failed to affect
catalepsy, while higher doses of 10 or 20 mg/kg clearly
increased catalepsy duration. This discrepancy in results
could be due to the timing of administration of fluoxetine
in relation to haloperidol. In rats, fluoxetine displayed
differential effects on dopamine neurons in the ventral
tegmental area (VTA) compared with substantia nigra
pars compacta (SNC). Single i.p. injection of 2.5 mg/kg
fluoxetine increased the number of spontaneously active
dopamine neurons in SNC and VTA. In contrast, a single
injection of 5 mg/kg fluoxetine increased the number of
spontaneously active dopamine neurons in VTA (30).
Catalepsy duration was increased by the serotonin
receptor antagonist and reuptake inhibitor nefazodone in
accordance with the findings of Benazzi (31). The SSRIs
fluvoxamine and citalopram also enhanced the
haloperidol-induced catalepsy in the present study. In this
context, worsening of Parkinson's disease in man by
citalopram was reported (13). In rats, endogenous 5-HT
acting on 5-HT2C receptors tonically inhibits basal
dopamine release in the prefrontal cortex, while
stimulation of 5-HT2C receptors with an exogenous
agonist preferentially inhibits stimulated release (32).
Enhanced serotonergic neurotransmission thus acts to
336

Turk J Med Sci

inhibit dopamine release. Furthermore, haloperidol
administration in rats leads to an adaptive increase in 5HT2C signaling, which may contribute to abnormal motor
function associated with antipsychotic use (33), and
blocking 5-HT2C attenuates haloperidol-induced
catalepsy (34). SSRIs are thus expected to exert adverse
effects on the catalepsy induced by typical antipsychotics,
e.g. haloperidol, which was observed in the present
study.
Sertraline, another SSRI, on the other hand, inhibited
the catalepsy with the maximal effect observed at the
minimal dose used (5 mg/kg). With the higher dose of 20
mg/kg, the inhibitory effect of sertraline is reduced.
Sertraline appears to be a potent dopamine reuptake
inhibitor (35). This might explain the reduction of
catalepsy by sertraline observed in the present study. In
other studies, a decrease in haloperidol catalepsy in mice
was found after the administration of 1 or 5 mg/kg
sertraline (26).
Sibutramine is an anti-obesity drug with serotonin,
dopamine and noradrenaline reuptake inhibitory
properties (36). In the present study, the effect of
haloperidol was significantly and potently inhibited by
sibutramine. Studies indicated that sibutramine exhibits
neurochemical and behavioral dopaminomimetic activity
in vivo, which is mediated by dopamine reuptake
inhibition. Sibutramine antagonized methyl-4-phenyl1,2,3,6-tetrahydro-pyridine (MPTP)-induced dopamine
depletion in the mouse brain (37). It was also suggested
that the effect of sibutramine on energy expenditure in
rats is predominantly due to a dopamine-dependent
increase in locomotor activity (38). Sibutramine (5
mg/kg, p.o.) increased extracellular dopamine and 5-HT
levels in rat striatum (39).
In the present study, haloperidol-induced catalepsy
was also reduced by Hypericum perforatum extract. This
herbal remedy is widely used in the pharmacotherapy of
mild to moderate depression (40). The exact mechanism
of action is not yet clear, but an increase in brain levels of
serotonin, noradrenaline or dopamine has been observed,
suggesting a mechanism similar to that of SSRIs or
tricyclic antidepressants. However, hyperforin also
inhibits the uptake of gamma-aminobutyric acid (GABA)
and L-glutamate (17,18). In addition, authors have
suggested that Hypericum or its active principle
hyperforin may be acting as a reserpine-like drug (19).
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In conclusion, the present paper provides evidence for
worsening of haloperidol-induced catalepsy by the
administration of fluoxetine, fluvoxamine and citalopram.
It therefore looks as if enhancing serotonergic
neurotransmission would have adverse effect on
haloperidol-induced catalepsy. The study indicates an
anti-cataleptic effect of imipramine, amitriptyline,
sertraline, sibutramine and Hypericum perforatum. It is

December 2007

suggested
that
increasing
noradrenergic
neurotransmission and/or anti-muscarinic effects account
for the catalepsy-reducing effect of imipramine or
amitriptyline,
whereas
dopaminergic-enhancing
properties of sertraline, sibutramine and Hypericum
perforatum contribute at least in part to their catalepsyinhibitory effects.
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